SCHEMBL2483553

SCHEMBL2483553

CN(C)C(=O)N(C)c1cc[c]cc1

nearest known ligand 0.42

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
POLB P06746 1/20 0.32
KDM4E B2RXH2 1/20 0.32
KMT2A Q03164 1/20 0.32
RAB9A P51151 2/20 0.31
ALDH1A1 P00352 2/20 0.31
MAPT P10636 1/20 0.31
HPGD P15428 1/20 0.31
SMN1; SMN2 Q16637 3/20 0.31
MLYCD O95822 1/20 0.30
HSP90AA1 P07900 1/20 0.30
PDK2 Q15119 1/20 0.30
CHRNB2 P17787 1/20 0.30
CHRNB4 P30926 1/20 0.30
CHRNA3 P32297 1/20 0.30
CHRNA4 P43681 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL486173 0.80 SMN1; SMN2 (0.47) POLBKMT2ARAB9AALDH1A1MAPT
SCHEMBL6861323 0.80 KMT2A (0.36) POLBKDM4EKMT2ARAB9AALDH1A1
SCHEMBL5472705 0.79
SCHEMBL5404611 0.78 PLAU (0.33) POLBKDM4EKMT2ARAB9AALDH1A1
SCHEMBL762796 0.77 NPSR1 (0.52) POLBKDM4EKMT2ARAB9AALDH1A1
SCHEMBL9445258 0.76 KMT2A (0.33) KMT2AALDH1A1HPGD
SCHEMBL11046065 0.76 ALDH1A1 (0.50) KDM4EKMT2ARAB9AALDH1A1MAPT
SCHEMBL9254666 0.76 APP (0.42) ALDH1A1MAPTHPGDSMN1; SMN2
SCHEMBL5516357 0.75 KMT2A (0.38) KMT2ARAB9AALDH1A1MAPTSMN1; SMN2
SCHEMBL2535672 0.75 PGR (0.41) KMT2ARAB9AALDH1A1SMN1; SMN2CHRNB2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2010066357-A1 BENZOTHIAZOLE AMIDES FOR DETECTION OF AMYLOID BETA BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2010-06-17 WO claimed
EP-2376463-A1 BENZOTHIAZOLE AMIDES FOR DETECTION OF AMYLOID BETA Bayer Pharma Aktiengesellschaft (DE) 2011-10-19 EP disclosed
US-20110250137-A1 RADIOISOTOPE-LABELED LYSINE AND ORNITHINE DERIVATIVES, THEIR USE AND PROCESSES FOR THEIR PREPARATION BAYER SCHERING PHARMA AKTIENGESELLCHAFT (DE) 2011-10-13 US disclosed
EP-2373597-A2 RADIOISOTOPE-LABELED LYSINE AND ORNITHINE DERIVATIVES, THEIR USE AND PROCESSES FOR THEIR PREPARATION Bayer Pharma Aktiengesellschaft (DE) 2011-10-12 EP disclosed
US-20110243846-A1 BENZOTHIAZOLE AMIDES FOR DETECTION OF AMYLOID BETA BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2011-10-06 US disclosed
WO-2010066357-A1 BENZOTHIAZOLE AMIDES FOR DETECTION OF AMYLOID BETA BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2010-06-17 WO disclosed
WO-2010063403-A2 RADIOISOTOPE-LABELED LYSINE AND ORNITHINE DERIVATIVES, THEIR USE AND PROCESSES FOR THEIR PREPARATION BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2010-06-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110250137-A1 RADIOISOTOPE-LABELED LYSINE AND ORNITHINE DERIVATIVES, THEIR USE AND PROCESSES FOR THEIR PREPARATION ODC1, OTC, ARG1 POLB 507/4885KDM4E 74/4885KMT2A 180/4885
US-20110243846-A1 BENZOTHIAZOLE AMIDES FOR DETECTION OF AMYLOID BETA APP, APBA1, BACE1 POLB 1500/4885KDM4E 3043/4885KMT2A 2763/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.